相似文献
1
Intrathecal IgM production at clinical onset correlates with a more severe disease course in multiple sclerosis.
J Neurol Neurosurg Psychiatry. 2006 Aug;77(8):953-5. doi: 10.1136/jnnp.2005.086116. Epub 2006 Mar 30.
2
Intrathecal IgM index correlates with a severe disease course in multiple sclerosis: Clinical and MRI results.
Clin Neurol Neurosurg. 2017 Sep;160:27-29. doi: 10.1016/j.clineuro.2017.05.026. Epub 2017 Jun 1.
3
Intrathecal immunoglobulin M synthesis in multiple sclerosis. Relationship with clinical and cerebrospinal fluid parameters.
Brain. 1991 Feb;114 ( Pt 1A):181-95.
4
Intrathecal IgM synthesis in pediatric MS is not a negative prognostic marker of disease progression: quantitative versus qualitative IgM analysis.
Mult Scler. 2011 Mar;17(3):327-34. doi: 10.1177/1352458510388543. Epub 2010 Dec 1.
5
Intrathecal synthesis of IgM measured after a first demyelinating event suggestive of multiple sclerosis is associated with subsequent MRI brain lesion accrual.
Mult Scler. 2012 May;18(5):587-91. doi: 10.1177/1352458511424589. Epub 2011 Sep 30.
6
Intrathecal IgM synthesis predicts the onset of new relapses and a worse disease course in MS.
Neurology. 2002 Aug 27;59(4):555-9. doi: 10.1212/wnl.59.4.555.
7
Cerebrospinal fluid IgM index correlates with cranial MRI lesion load in patients with multiple sclerosis.
Eur Neurol. 2007;58(2):90-5. doi: 10.1159/000103643. Epub 2007 Jun 12.
8
A multifactorial prognostic index in multiple sclerosis. Cerebrospinal fluid IgM oligoclonal bands and clinical features to predict the evolution of the disease.
J Neurol. 2008 Jul;255(7):1023-31. doi: 10.1007/s00415-008-0827-5. Epub 2008 Jun 13.
9
Intrathecal IgM synthesis in neurologic diseases: relationship with disability in MS.
Neurology. 2002 Mar 12;58(5):824-6. doi: 10.1212/wnl.58.5.824.
10
Frequency of an intrathecal IgM synthesis and MRZ reaction in children with MS.
Eur J Paediatr Neurol. 2024 May;50:51-56. doi: 10.1016/j.ejpn.2024.04.005. Epub 2024 Apr 16.
引用本文的文献
1
Predictors of early disability accumulation in newly diagnosed multiple sclerosis: clinical, imaging and cerebrospinal fluid measures.
J Neurol Neurosurg Psychiatry. 2025 Feb 17. doi: 10.1136/jnnp-2024-335037.
2
Measuring Disease Progression in Multiple Sclerosis Clinical Drug Trials and Impact on Future Patient Care.
CNS Drugs. 2025 Jan;39(1):55-80. doi: 10.1007/s40263-024-01132-w. Epub 2024 Nov 24.
3
Cell-binding IgM in CSF is distinctive of multiple sclerosis and targets the iron transporter SCARA5.
Brain. 2024 Mar 1;147(3):839-848. doi: 10.1093/brain/awad424.
4
Cerebrospinal fluid-related tissue damage in multiple sclerosis patients with iron rim lesions.
Mult Scler. 2023 Apr;29(4-5):549-558. doi: 10.1177/13524585231155639. Epub 2023 Feb 19.
5
Mitochondrial Impairments in Peripheral Blood Mononuclear Cells of Multiple Sclerosis Patients.
Biology (Basel). 2022 Nov 8;11(11):1633. doi: 10.3390/biology11111633.
6
Using personalized prognosis in the treatment of relapsing multiple sclerosis: A practical guide.
Front Immunol. 2022 Sep 27;13:991291. doi: 10.3389/fimmu.2022.991291. eCollection 2022.
7
Increased intrathecal neurofilament light and immunoglobulin M predict severe disability in relapsing-remitting multiple sclerosis.
Front Immunol. 2022 Aug 10;13:967953. doi: 10.3389/fimmu.2022.967953. eCollection 2022.
8
Contribution of Dysregulated B-Cells and IgE Antibody Responses to Multiple Sclerosis.
Front Immunol. 2022 Jun 16;13:900117. doi: 10.3389/fimmu.2022.900117. eCollection 2022.
9
IL-2, IL-6 and chitinase 3-like 2 might predict early relapse activity in multiple sclerosis.
PLoS One. 2022 Jun 27;17(6):e0270607. doi: 10.1371/journal.pone.0270607. eCollection 2022.
10
Assessing the presence of oligoclonal IgM bands as a prognostic biomarker of cognitive decline in the early stages of multiple sclerosis.
Brain Behav. 2021 Dec;11(12):e2405. doi: 10.1002/brb3.2405. Epub 2021 Nov 18.
本文引用的文献
1
Intrathecal synthesis of oligoclonal IgM against myelin lipids predicts an aggressive disease course in MS.
J Clin Invest. 2005 Jan;115(1):187-94. doi: 10.1172/JCI22833.
2
Recapitulation of B cell differentiation in the central nervous system of patients with multiple sclerosis.
Proc Natl Acad Sci U S A. 2004 Jul 27;101(30):11064-9. doi: 10.1073/pnas.0402455101. Epub 2004 Jul 19.
3
Neuropathology of multiple sclerosis-new concepts.
Brain Res Bull. 2003 Aug 15;61(3):321-6. doi: 10.1016/s0361-9230(03)00095-9.
4
Intrathecal IgM synthesis is a prognostic factor in multiple sclerosis.
Ann Neurol. 2003 Feb;53(2):222-6. doi: 10.1002/ana.10441.
5
Intrathecal IgM synthesis predicts the onset of new relapses and a worse disease course in MS.
Neurology. 2002 Aug 27;59(4):555-9. doi: 10.1212/wnl.59.4.555.
6
Intrathecal IgM synthesis in neurologic diseases: relationship with disability in MS.
Neurology. 2002 Mar 12;58(5):824-6. doi: 10.1212/wnl.58.5.824.
7
Origins and functions of B-1 cells with notes on the role of CD5.
Annu Rev Immunol. 2002;20:253-300. doi: 10.1146/annurev.immunol.20.100301.064833. Epub 2001 Oct 4.
8
The membrane attack complex of complement causes severe demyelination associated with acute axonal injury.
J Immunol. 2002 Jan 1;168(1):458-65. doi: 10.4049/jimmunol.168.1.458.
9
Heterogeneity of multiple sclerosis pathogenesis: implications for diagnosis and therapy.
Trends Mol Med. 2001 Mar;7(3):115-21. doi: 10.1016/s1471-4914(00)01909-2.
10
MBP, anti-MBP and anti-PLP antibodies, and intrathecal complement activation in multiple sclerosis.
Mult Scler. 1998 Jun;4(3):127-31. doi: 10.1177/135245859800400307.
Zotero 插件